Zymenex enzyme moves into Phase 2b clinical trials in patients with the rare disease alpha-Mannosidosis
Zymenex enzyme gets US Orphan Drug Designation Approval from FDA
Positive clinical effect in Phase 2 trial in patients with the rare disease alpha-Mannosidosis
Zymenex enzyme gets EU Orphan Drug Designation Approval
Zymenex enzyme in Phase 2 clinical trials in patients with the rare disease alpha-Mannosidosis
Zymenex enzyme gets EU-millions for clinical trials in ALPHA-MAN project
Zymenex receives 500.000 dkr from the Advisory Council on Technology for a collaborative technology with Danish Technological Institute
Natural History Study of Krabbe Disease underway in the US
Zymenex acquires ACE Biosciences
Positive CNS/PNS effect data in Alpha-mannosidosis mouse model presented in Prague